[go: up one dir, main page]

WO2008014299A3 - Use of an alpha2-agonist composition for the treatment of hyperlipidemia - Google Patents

Use of an alpha2-agonist composition for the treatment of hyperlipidemia Download PDF

Info

Publication number
WO2008014299A3
WO2008014299A3 PCT/US2007/074284 US2007074284W WO2008014299A3 WO 2008014299 A3 WO2008014299 A3 WO 2008014299A3 US 2007074284 W US2007074284 W US 2007074284W WO 2008014299 A3 WO2008014299 A3 WO 2008014299A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperlipidemia
alpha2
treatment
agonist composition
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/074284
Other languages
French (fr)
Other versions
WO2008014299A2 (en
Inventor
Jyotirmoy X Kusari
Daniel W Gil
John E Donello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO2008014299A2 publication Critical patent/WO2008014299A2/en
Publication of WO2008014299A3 publication Critical patent/WO2008014299A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is the use of an agonist of the alpha2B and/or alρha2C adrenergic receptor subtypes that lacks (a) significant alpha2A adrenergic receptor activity or (b) significant alphalA adrenergic receptor activity, or that lacks both (a) and (b) for treating hyperglycemia or hyperlipidemia.
PCT/US2007/074284 2006-07-27 2007-07-25 Use of an alpha2-agonist composition for the treatment of hyperlipidemia Ceased WO2008014299A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82052606P 2006-07-27 2006-07-27
US60/820,526 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008014299A2 WO2008014299A2 (en) 2008-01-31
WO2008014299A3 true WO2008014299A3 (en) 2008-04-24

Family

ID=38825013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074284 Ceased WO2008014299A2 (en) 2006-07-27 2007-07-25 Use of an alpha2-agonist composition for the treatment of hyperlipidemia

Country Status (1)

Country Link
WO (1) WO2008014299A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046239A1 (en) * 1996-06-06 1997-12-11 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US20020161051A1 (en) * 2001-02-27 2002-10-31 Allergan Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
WO2003030903A1 (en) * 2001-10-05 2003-04-17 Arachnova Therapeutics Ltd. The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion
US20050075366A1 (en) * 2002-05-21 2005-04-07 Heidelbaugh Todd M. 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
WO2005034849A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods for identifying improved, non-sedating alpha-2 agonists
WO2007090733A1 (en) * 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy derivatives suitable as alpha2 adrenergic receptor agonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046239A1 (en) * 1996-06-06 1997-12-11 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US20020161051A1 (en) * 2001-02-27 2002-10-31 Allergan Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
WO2003030903A1 (en) * 2001-10-05 2003-04-17 Arachnova Therapeutics Ltd. The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion
US20050075366A1 (en) * 2002-05-21 2005-04-07 Heidelbaugh Todd M. 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
WO2005034849A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods for identifying improved, non-sedating alpha-2 agonists
WO2007090733A1 (en) * 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy derivatives suitable as alpha2 adrenergic receptor agonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALAZOVJECH I ET AL: "The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension.", COR ET VASA, VOL. 29, NO. 4 SUPPL 1, PP. 46-52. JOURNAL CODE: 0372614. ISSN: 0010-8650., 1987, XP008088535 *
REITER J ET AL: "SYNTHESIS OF NEW BENZYL THIO UREA DERIVATIVES AND THEIR CYCLIC ANALOGS WITH DIURETIC AND SALURETIC ACTIVITY", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 1, 1980, pages 41 - 53, XP001109342, ISSN: 0223-5234 *
SATIA MILAN C ET AL: "Beneficial effects of clonidine in streptozotocin-induced diabetes and DOCA-hypertensive rats", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 49, no. 10, October 1997 (1997-10-01), pages 1030 - 1035, XP008088536, ISSN: 0022-3573 *
VELLIQUETTE RODNEY A ET AL: "Contrasting metabolic effects of antihypertensive agents.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 307, no. 3, December 2003 (2003-12-01), pages 1104 - 1111, XP002470476, ISSN: 0022-3565 *
VELLIQUETTE RODNEY A ET AL: "Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (2006 JAN) VOL. 372, NO. 4, PP. 300-12. ELECTRONIC PUBLICATION: 2006-01-17. JOURNAL CODE: 0326264. ISSN: 0028-1298., 17 January 2006 (2006-01-17), XP019326113 *

Also Published As

Publication number Publication date
WO2008014299A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2009129433A3 (en) Alpha adrenergic receptor agonists for treatment of degenerative disc disease
WO2007133518A3 (en) Modulating agents for antimicrobial coatings
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
WO2008087491A8 (en) Method for treating or preventing symptoms of hormonal variations
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
WO2008100457A3 (en) Functionally selective alpha2c adrenoreceptor agonists
PT2040755E (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
PT2142519E (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
TWI348342B (en) Method of setting reference value for examining substrate, and device and program using the same
PT1986642E (en) Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
CL2007002888A1 (en) COMPOUNDS DERIVED FROM N-METANSULPHONYLAMINE AMIDAS, METALOPROTEASE MATRIX INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF A CELL PROLIFERATION DISORDER.
WO2010033495A3 (en) Functionally selective azanitrile alpha2c adrenoreceptor agonists
WO2008100456A3 (en) Functionally selective alpha2c adrenoreceptor agonists
UA96573C2 (en) Kinin antagonists for treating bladder dysfunction
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2055695A4 (en) Composition for alkylation, and method for detoxification of toxic compound using the composition
WO2008014299A3 (en) Use of an alpha2-agonist composition for the treatment of hyperlipidemia
WO2007118073A3 (en) Obesity and body fat distribution

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813322

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813322

Country of ref document: EP

Kind code of ref document: A2